Gollnick H, Orfanos C E
Z Hautkr. 1981 Sep 15;56(18):1183-96.
The serum lipid levels were repeatedly controlled in 25 patients with various skin diseases treated orally with retinoid Ro 10-9359 in different doses. In 19 cases serum lipid values before onset of treatment were taken. 6 additional patients were controlled after long-term intake of the drug over 6-8 months. Pathological elevations of triglycerides were seen in 5 patients, in 4 of them 2-12 weeks after onset of oral treatment. All patients with elevated values had additional risk factors: Manifest or asymptomatic diabetes, alcoholic abuse with fatty liver, adipositas, and/or preexisting disorders of lipid metabolism. The observed changes seemed dose-dependent. The values were lowered or returned to normal after dose reduction or after discontinuation of treatment (one case). The cholesterin levels also showed some elevated values during the time of observation, however, there was no clear relation to the administration of the drug and the daily dose. The changes were also seen preferably in patients with risk factors. Controls of serum lipid levels seem, therefore, indicated before and under administration of oral retinoid. In patients with the additional risk factors mentioned above strict indication for oral retinoid therapy is needed and lower doses should be rather administered.
对25例口服不同剂量维甲酸Ro 10-9359治疗的各种皮肤病患者的血脂水平进行了反复监测。19例患者记录了治疗开始前的血脂值。另外6例患者在长期服用该药物6-8个月后进行了监测。5例患者出现甘油三酯病理性升高,其中4例在口服治疗开始后2-12周出现。所有血脂值升高的患者都有其他危险因素:显性或无症状糖尿病、伴有脂肪肝的酒精滥用、肥胖症和/或既往存在的脂质代谢紊乱。观察到的变化似乎与剂量有关。剂量减少或停药后(1例),血脂值降低或恢复正常。在观察期间,胆固醇水平也有一些升高值,然而,与药物给药和每日剂量没有明确关系。这些变化也多见于有危险因素的患者。因此,在口服维甲酸之前和用药期间似乎有必要监测血脂水平。对于上述有其他危险因素的患者,口服维甲酸治疗需要严格掌握适应证,且应使用较低剂量。